Trial Highlights

SBT-20 is Stealth’s second pipeline candidate and is being developed for the treatment of neurodegenerative diseases. SBT-20 is an investigational tetrapeptide with the potential to slow neuronal degeneration and disease progression in Huntington’s disease by improving mitochondrial function.

In preclinical studies, SBT-20 has demonstrated an enhanced ability to target the central nervous system, by achieving higher concentrations and extended stability in the cerebrospinal fluid compared with elamipretide.

SBT-20 in Clinical Studies

Neurodegenerative Diseases